Anti-angiogenesis: the challenges ahead.
Mariani
Sara M
SM
Medscape General Medicine.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D042501:Angiogenic Proteins / Q000037:antagonists & inhibitors / Q000097:blood; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D000068258:Bevacizumab; D001632:Bibenzyls / Q000627:therapeutic use; D001682:Biological Availability; D015415:Biomarkers; D002292:Carcinoma, Renal Cell / Q000097:blood / Q000098:blood supply / Q000188:drug therapy / Q000556:secondary; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D043169:Endostatins / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology; D006131:Growth Inhibitors / Q000627:therapeutic use; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood / Q000098:blood supply / Q000188:drug therapy; D008870:Microtubules / Q000378:metabolism; D009369:Neoplasms / Q000097:blood / Q000098:blood supply* / Q000188:drug therapy / Q000532:radiotherapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000532:radiotherapy; D009864:Ontario; D040262:Receptors, Vascular Endothelial Growth Factor / Q000276:immunology; D013267:Stilbenes / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D042501:Angiogenic Proteins; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D001632:Bibenzyls; D015415:Biomarkers; D043169:Endostatins; D016228:Endothelial Growth Factors; D006131:Growth Inhibitors; D013267:Stilbenes; D000068258:Bevacizumab; C040105:combretastatin; D040262:Receptors, Vascular Endothelial Growth Factor